BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee JH, Choy ML, Ngo L, Foster SS, Marks PA. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA. 2010;107:14639-14644. [PMID: 20679231 DOI: 10.1073/pnas.1008522107] [Cited by in Crossref: 234] [Cited by in F6Publishing: 225] [Article Influence: 19.5] [Reference Citation Analysis]
Number Citing Articles
1 Iwamoto FM, Lamborn KR, Kuhn JG, Wen PY, Yung WK, Gilbert MR, Chang SM, Lieberman FS, Prados MD, Fine HA. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol 2011;13:509-16. [PMID: 21377994 DOI: 10.1093/neuonc/nor017] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 6.5] [Reference Citation Analysis]
2 Nandakumar V, Hansen N, Glenn HL, Han JH, Helland S, Hernandez K, Senechal P, Johnson RH, Bussey KJ, Meldrum DR. Vorinostat differentially alters 3D nuclear structure of cancer and non-cancerous esophageal cells. Sci Rep 2016;6:30593. [PMID: 27503568 DOI: 10.1038/srep30593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Muschen M, Grant S. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res 2011;17:3219-32. [PMID: 21474579 DOI: 10.1158/1078-0432.CCR-11-0234] [Cited by in Crossref: 59] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
4 Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487:482-485. [PMID: 22837004 DOI: 10.1038/nature11286] [Cited by in Crossref: 805] [Cited by in F6Publishing: 759] [Article Influence: 80.5] [Reference Citation Analysis]
5 Dasmahapatra G, Patel H, Friedberg J, Quayle SN, Jones SS, Grant S. In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells. Mol Cancer Ther 2014;13:2886-97. [PMID: 25239935 DOI: 10.1158/1535-7163.MCT-14-0220] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
6 Cleaver JE. γH2Ax: biomarker of damage or functional participant in DNA repair "all that glitters is not gold!". Photochem Photobiol 2011;87:1230-9. [PMID: 21883247 DOI: 10.1111/j.1751-1097.2011.00995.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 7.3] [Reference Citation Analysis]
7 Karakaidos P, Karagiannis D, Rampias T. Resolving DNA Damage: Epigenetic Regulation of DNA Repair. Molecules 2020;25:E2496. [PMID: 32471288 DOI: 10.3390/molecules25112496] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
8 Zhang H, Dong L, Chen Q, Kong L, Meng B, Wang H, Fu K, Wang X, Pan-hammarström Q, Wang P, Wang X. Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma. Leukemia Research 2017;56:29-35. [DOI: 10.1016/j.leukres.2017.01.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
9 Duncan HF, Smith AJ, Fleming GJ, Cooper PR. Histone deacetylase inhibitors epigenetically promote reparative events in primary dental pulp cells. Experimental Cell Research 2013;319:1534-43. [DOI: 10.1016/j.yexcr.2013.02.022] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
10 Zhang C, Zhai S, Li X, Zhang Q, Wu L, Liu Y, Jiang C, Zhou H, Li F, Zhang S, Su G, Zhang B, Yan B. Synergistic action by multi-targeting compounds produces a potent compound combination for human NSCLC both in vitro and in vivo. Cell Death Dis 2014;5:e1138. [PMID: 24651441 DOI: 10.1038/cddis.2014.76] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
11 Zhou L, Chen S, Zhang Y, Kmieciak M, Leng Y, Li L, Lin H, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Rahmani M, Povirk L, Chalasani S, Berger AJ, Dai Y, Grant S. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. Blood 2016;127:2219-30. [PMID: 26851293 DOI: 10.1182/blood-2015-06-653717] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
12 Kim JS, Lee SC, Min HY, Park KH, Hyun SY, Kwon SJ, Choi SP, Kim WY, Lee HJ, Lee HY. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors. Cancer Lett 2015;361:197-206. [PMID: 25721083 DOI: 10.1016/j.canlet.2015.02.038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
13 Lavelle D, Engel JD, Saunthararajah Y. Fetal Hemoglobin Induction by Epigenetic Drugs. Semin Hematol 2018;55:60-7. [PMID: 29958562 DOI: 10.1053/j.seminhematol.2018.04.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
14 Kolbinger FR, Koeneke E, Ridinger J, Heimburg T, Müller M, Bayer T, Sippl W, Jung M, Gunkel N, Miller AK, Westermann F, Witt O, Oehme I. The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines. Arch Toxicol 2018;92:2649-64. [PMID: 29947893 DOI: 10.1007/s00204-018-2234-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
15 Saunthararajah Y, Triozzi P, Rini B, Singh A, Radivoyevitch T, Sekeres M, Advani A, Tiu R, Reu F, Kalaycio M, Copelan E, Hsi E, Lichtin A, Bolwell B. p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol 2012;39:97-108. [PMID: 22289496 DOI: 10.1053/j.seminoncol.2011.11.011] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
16 Perona M, Rodríguez C, Carpano M, Thomasz L, Nievas S, Olivera M, Thorp S, Curotto P, Pozzi E, Kahl S, Pisarev M, Juvenal G, Dagrosa A. Improvement of the boron neutron capture therapy (BNCT) by the previous administration of the histone deacetylase inhibitor sodium butyrate for the treatment of thyroid carcinoma. Radiat Environ Biophys 2013;52:363-73. [PMID: 23636505 DOI: 10.1007/s00411-013-0470-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
17 Novohradsky V, Zerzankova L, Stepankova J, Vrana O, Raveendran R, Gibson D, Kasparkova J, Brabec V. Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands. J Inorg Biochem 2014;140:72-9. [PMID: 25063910 DOI: 10.1016/j.jinorgbio.2014.07.004] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
18 Kommalapati VK, Kumar D, Tangutur AD. Inhibition of JNJ-26481585-mediated autophagy induces apoptosis via ROS activation and mitochondrial membrane potential disruption in neuroblastoma cells. Mol Cell Biochem 2020;468:21-34. [PMID: 32146648 DOI: 10.1007/s11010-020-03708-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Barrilleaux B, Knoepfler PS. Inducing iPSCs to escape the dish. Cell Stem Cell 2011;9:103-11. [PMID: 21816362 DOI: 10.1016/j.stem.2011.07.006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 5.0] [Reference Citation Analysis]
20 Dell'Aversana C, Lepore I, Altucci L. HDAC modulation and cell death in the clinic. Exp Cell Res 2012;318:1229-44. [PMID: 22336671 DOI: 10.1016/j.yexcr.2012.01.025] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
21 Mrakovcic M, Fröhlich LF. Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy. Cancers (Basel) 2019;12:E109. [PMID: 31906235 DOI: 10.3390/cancers12010109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
22 Anantharaju PG, Reddy BD, Padukudru MA, Kumari Chitturi CM, Vimalambike MG, Madhunapantula SV. Naturally occurring benzoic acid derivatives retard cancer cell growth by inhibiting histone deacetylases (HDAC). Cancer Biol Ther 2017;18:492-504. [PMID: 28506198 DOI: 10.1080/15384047.2017.1324374] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
23 Robey RW, Chakraborty AR, Basseville A, Luchenko V, Bahr J, Zhan Z, Bates SE. Histone deacetylase inhibitors: emerging mechanisms of resistance. Mol Pharm 2011;8:2021-31. [PMID: 21899343 DOI: 10.1021/mp200329f] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 7.4] [Reference Citation Analysis]
24 Gaupel AC, Begley TJ, Tenniswood M. Gcn5 Modulates the Cellular Response to Oxidative Stress and Histone Deacetylase Inhibition. J Cell Biochem 2015;116:1982-92. [PMID: 25755069 DOI: 10.1002/jcb.25153] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
25 Johnson AM, Bennett PV, Sanidad KZ, Hoang A, Jardine JH, Keszenman DJ, Wilson PF. Evaluation of Histone Deacetylase Inhibitors as Radiosensitizers for Proton and Light Ion Radiotherapy. Front Oncol 2021;11:735940. [PMID: 34513712 DOI: 10.3389/fonc.2021.735940] [Reference Citation Analysis]
26 Yin L, Liu Y, Peng Y, Peng Y, Yu X, Gao Y, Yuan B, Zhu Q, Cao T, He L, Gong Z, Sun L, Fan X, Li X. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells. J Exp Clin Cancer Res 2018;37:153. [PMID: 30012171 DOI: 10.1186/s13046-018-0810-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
27 Pinkerneil M, Hoffmann MJ, Kohlhof H, Schulz WA, Niegisch G. Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines. Target Oncol 2016;11:783-98. [PMID: 27250763 DOI: 10.1007/s11523-016-0444-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
28 Selli C, Turnbull AK, Pearce DA, Li A, Fernando A, Wills J, Renshaw L, Thomas JS, Dixon JM, Sims AH. Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours. Breast Cancer Res 2019;21:2. [PMID: 30616553 DOI: 10.1186/s13058-018-1089-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
29 Jenke R, Reßing N, Hansen FK, Aigner A, Büch T. Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives. Cancers (Basel) 2021;13:634. [PMID: 33562653 DOI: 10.3390/cancers13040634] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
30 Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015;20:3898-3941. [PMID: 25738536 DOI: 10.3390/molecules20033898] [Cited by in Crossref: 415] [Cited by in F6Publishing: 378] [Article Influence: 59.3] [Reference Citation Analysis]
31 Manzotti G, Ciarrocchi A, Sancisi V. Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy. Cancers (Basel) 2019;11:E304. [PMID: 30841549 DOI: 10.3390/cancers11030304] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
32 Mascaro-Cordeiro B, Oliveira ID, Tesser-Gamba F, Pavon LF, Saba-Silva N, Cavalheiro S, Dastoli P, Toledo SRC. Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma. Childs Nerv Syst 2018;34:1497-509. [PMID: 29785653 DOI: 10.1007/s00381-018-3817-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
33 Kerns SL, Chuang KH, Hall W, Werner Z, Chen Y, Ostrer H, West C, Rosenstein B. Radiation biology and oncology in the genomic era. Br J Radiol 2018;91:20170949. [PMID: 29888979 DOI: 10.1259/bjr.20170949] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
34 Xue Z, Lui VWY, Li Y, Jia L, You C, Li X, Piao W, Yuan H, Khong PL, Lo KW, Cheung LWT, Lee VHF, Lee AWM, Tsao SW, Tsang CM. Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma. J Exp Clin Cancer Res 2020;39:262. [PMID: 33243298 DOI: 10.1186/s13046-020-01763-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Miles MA, Harris MA, Hawkins CJ. Proteasome inhibitors trigger mutations via activation of caspases and CAD, but mutagenesis provoked by the HDAC inhibitors vorinostat and romidepsin is caspase/CAD-independent. Apoptosis 2019;24:404-13. [PMID: 30997620 DOI: 10.1007/s10495-019-01543-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
36 Singh BN, Zhou H, Li J, Tipton T, Wang B, Shao G, Gilbert EN, Li Q, Jiang SW. Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers. Future Oncol 2011;7:1415-28. [PMID: 22112317 DOI: 10.2217/fon.11.124] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
37 Gong F, Chiu LY, Miller KM. Acetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and Cancer. PLoS Genet 2016;12:e1006272. [PMID: 27631103 DOI: 10.1371/journal.pgen.1006272] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 10.5] [Reference Citation Analysis]
38 Mueller S, Yang X, Sottero TL, Gragg A, Prasad G, Polley MY, Weiss WA, Matthay KK, Davidoff AM, DuBois SG, Haas-Kogan DA. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett 2011;306:223-9. [PMID: 21497989 DOI: 10.1016/j.canlet.2011.03.010] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
39 Newbold A, Falkenberg KJ, Prince HM, Johnstone RW. How do tumor cells respond to HDAC inhibition? FEBS J 2016;283:4032-46. [PMID: 27112360 DOI: 10.1111/febs.13746] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 11.0] [Reference Citation Analysis]
40 Li Z, Chen Y, Tang M, Li Y, Zhu W. Regulation of DNA damage-induced ATM activation by histone modifications. GENOME INSTAB DIS 2020;1:20-33. [DOI: 10.1007/s42764-019-00004-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Silva G, Cardoso BA, Belo H, Almeida AM. Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms. PLoS One 2013;8:e53766. [PMID: 23320102 DOI: 10.1371/journal.pone.0053766] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
42 Zhou L, Zhang Y, Chen S, Kmieciak M, Leng Y, Lin H, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Dai Y. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Leukemia. 2015;29:807-818. [PMID: 25283841 DOI: 10.1038/leu.2014.296] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
43 Lee YJ, Won AJ, Lee J, Jung JH, Yoon S, Lee BM, Kim HS. Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells. Int J Med Sci 2012;9:881-93. [PMID: 23155362 DOI: 10.7150/ijms.5011] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 6.3] [Reference Citation Analysis]
44 Aleksandrov R, Hristova R, Stoynov S, Gospodinov A. The Chromatin Response to Double-Strand DNA Breaks and Their Repair. Cells 2020;9:E1853. [PMID: 32784607 DOI: 10.3390/cells9081853] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
45 Hui KF, Chiang AK. Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism. Int J Cancer 2014;135:2950-61. [PMID: 24771510 DOI: 10.1002/ijc.28924] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
46 Vesci L, Bernasconi E, Milazzo FM, De Santis R, Gaudio E, Kwee I, Rinaldi A, Pace S, Carollo V, Giannini G, Bertoni F. Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor. Oncotarget 2015;6:5735-48. [PMID: 25671299 DOI: 10.18632/oncotarget.3240] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
47 Lamparter C, Winn LM. Tissue-specific effects of valproic acid on DNA repair genes and apoptosis in postimplantation mouse embryos. Toxicol Sci 2014;141:59-67. [PMID: 24913804 DOI: 10.1093/toxsci/kfu105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
48 Luo Y, Wang H, Zhao X, Dong C, Zhang F, Guo G, Guo G, Wang X, Powell SN, Feng Z. Valproic acid causes radiosensitivity of breast cancer cells via disrupting the DNA repair pathway. Toxicol Res (Camb) 2016;5:859-70. [PMID: 30090395 DOI: 10.1039/c5tx00476d] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
49 Karagiannis TC, Lin AJ, Ververis K, Chang L, Tang MM, Okabe J, El-Osta A. Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes. Aging (Albany NY) 2010;2:659-68. [PMID: 20930262 DOI: 10.18632/aging.100203] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
50 Revet I, Feeney L, Bruguera S, Wilson W, Dong TK, Oh DH, Dankort D, Cleaver JE. Functional relevance of the histone gammaH2Ax in the response to DNA damaging agents. Proc Natl Acad Sci U S A 2011;108:8663-7. [PMID: 21555580 DOI: 10.1073/pnas.1105866108] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 7.5] [Reference Citation Analysis]
51 Roos WP, Krumm A. The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair. Nucleic Acids Res 2016;44:10017-30. [PMID: 27738139 DOI: 10.1093/nar/gkw922] [Cited by in Crossref: 18] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
52 Sultana F, Manasa KL, Shaik SP, Bonam SR, Kamal A. Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update. Curr Med Chem 2019;26:7212-80. [PMID: 29852860 DOI: 10.2174/0929867325666180530094120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
53 Hsieh YJ, Hwu L, Chen YC, Ke CC, Chen FD, Wang HE, Lin KP, Yeh HH, Chang CW, Liu RS. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor. J Nucl Med 2014;55:678-85. [PMID: 24639460 DOI: 10.2967/jnumed.113.126573] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
54 Zhang XF, Huang FH, Zhang GL, Bai DP, Massimo DF, Huang YF, Gurunathan S. Novel biomolecule lycopene-reduced graphene oxide-silver nanoparticle enhances apoptotic potential of trichostatin A in human ovarian cancer cells (SKOV3). Int J Nanomedicine 2017;12:7551-75. [PMID: 29075115 DOI: 10.2147/IJN.S144161] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 6.2] [Reference Citation Analysis]
55 Bountra C, Oppermann U, Heightman TD. Animal models of epigenetic regulation in neuropsychiatric disorders. Curr Top Behav Neurosci 2011;7:281-322. [PMID: 21225415 DOI: 10.1007/7854_2010_104] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
56 Nalabothula N, Carrier F. Cancer cells' epigenetic composition and predisposition to histone deacetylase inhibitor sensitization. Epigenomics 2011;3:145-55. [PMID: 21743813 DOI: 10.2217/epi.11.12] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
57 Zhou X, Hua X, Ding X, Bian Y, Wang X. Trichostatin Differentially Regulates Th1 and Th2 Responses and Alleviates Rheumatoid Arthritis in Mice. J Clin Immunol 2011;31:395-405. [DOI: 10.1007/s10875-011-9508-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
58 di Masi A, Cilli D, Berardinelli F, Talarico A, Pallavicini I, Pennisi R, Leone S, Antoccia A, Noguera NI, Lo-Coco F, Ascenzi P, Minucci S, Nervi C. PML nuclear body disruption impairs DNA double-strand break sensing and repair in APL. Cell Death Dis 2016;7:e2308. [PMID: 27468685 DOI: 10.1038/cddis.2016.115] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
59 White CA, Pone EJ, Lam T, Tat C, Hayama KL, Li G, Zan H, Casali P. Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses. J Immunol 2014;193:5933-50. [PMID: 25392531 DOI: 10.4049/jimmunol.1401702] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 8.4] [Reference Citation Analysis]
60 Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget 2014;5:6558-72. [PMID: 25115382 DOI: 10.18632/oncotarget.2289] [Cited by in Crossref: 98] [Cited by in F6Publishing: 93] [Article Influence: 14.0] [Reference Citation Analysis]
61 Ouyang DY, Ji YH, Saltis M, Xu LH, Zhang YT, Zha QB, Cai JY, He XH. Valproic acid synergistically enhances the cytotoxicity of gossypol in DU145 prostate cancer cells: an iTRTAQ-based quantitative proteomic analysis. J Proteomics 2011;74:2180-93. [PMID: 21726675 DOI: 10.1016/j.jprot.2011.06.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
62 Dasmahapatra G, Patel H, Nguyen T, Attkisson E, Grant S. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res 2013;19:404-14. [PMID: 23204129 DOI: 10.1158/1078-0432.CCR-12-2799] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
63 Smith S, Fox J, Mejia M, Ruangpradit W, Saberi A, Kim S, Choi Y, Oh S, Wang Y, Choi K, Li L, Hendrickson EA, Takeda S, Muller M, Myung K. Histone deacetylase inhibitors selectively target homology dependent DNA repair defective cells and elevate non-homologous endjoining activity. PLoS One 2014;9:e87203. [PMID: 24466340 DOI: 10.1371/journal.pone.0087203] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
64 Lamichhane P, Maiolini M, Alnafoosi O, Hussein S, Alnafoosi H, Umbela S, Richardson T, Alla N, Lamichhane N, Subhadra B, Deshmukh RR. Colorectal Cancer and Probiotics: Are Bugs Really Drugs? Cancers (Basel) 2020;12:E1162. [PMID: 32380712 DOI: 10.3390/cancers12051162] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
65 Rødland GE, Melhus K, Generalov R, Gilani S, Bertoni F, Dahle J, Syljuåsen RG, Patzke S. The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines. Front Oncol 2019;9:1301. [PMID: 31850205 DOI: 10.3389/fonc.2019.01301] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
66 Bieszczad B, Garbicz D, Świtalska M, Dudek MK, Warszycki D, Wietrzyk J, Grzesiuk E, Mieczkowski A. Improved HDAC Inhibition, Stronger Cytotoxic Effect and Higher Selectivity against Leukemias and Lymphomas of Novel, Tricyclic Vorinostat Analogues. Pharmaceuticals (Basel) 2021;14:851. [PMID: 34577551 DOI: 10.3390/ph14090851] [Reference Citation Analysis]
67 Dai Y, Chen S, Kmieciak M, Zhou L, Lin H, Pei XY, Grant S. The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. Mol Cancer Ther 2013;12:878-89. [PMID: 23536721 DOI: 10.1158/1535-7163.MCT-12-0902] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
68 Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget 2014;5:5637-50. [PMID: 25026298 DOI: 10.18632/oncotarget.2154] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 12.9] [Reference Citation Analysis]
69 Bezecny P. Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience. Med Oncol 2014;31:985. [PMID: 24838514 DOI: 10.1007/s12032-014-0985-5] [Cited by in Crossref: 59] [Cited by in F6Publishing: 65] [Article Influence: 7.4] [Reference Citation Analysis]
70 Biau J, Chautard E, Verrelle P, Dutreix M. Altering DNA Repair to Improve Radiation Therapy: Specific and Multiple Pathway Targeting. Front Oncol 2019;9:1009. [PMID: 31649878 DOI: 10.3389/fonc.2019.01009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
71 Li D, Yang Y, Wang S, He X, Liu M, Bai B, Tian C, Sun R, Yu T, Chu X. Role of acetylation in doxorubicin-induced cardiotoxicity. Redox Biol 2021;46:102089. [PMID: 34364220 DOI: 10.1016/j.redox.2021.102089] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
72 Flower A, Abla O. Resistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma. In: Xavier AC, Cairo MS, editors. Resistance to Targeted Therapies in Lymphomas. Cham: Springer International Publishing; 2019. pp. 87-110. [DOI: 10.1007/978-3-030-24424-8_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Ny L, Jespersen H, Karlsson J, Alsén S, Filges S, All-Eriksson C, Andersson B, Carneiro A, Helgadottir H, Levin M, Ljuslinder I, Olofsson Bagge R, Sah VR, Stierner U, Ståhlberg A, Ullenhag G, Nilsson LM, Nilsson JA. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. Nat Commun 2021;12:5155. [PMID: 34453044 DOI: 10.1038/s41467-021-25332-w] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 Li Y, Li Z, Zhu WG. Molecular Mechanisms of Epigenetic Regulators as Activatable Targets in Cancer Theranostics. Curr Med Chem 2019;26:1328-50. [PMID: 28933282 DOI: 10.2174/0929867324666170921101947] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
75 Marijon H, Lee DH, Ding L, Sun H, Gery S, de Gramont A, Koeffler HP. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells. Biomedicine & Pharmacotherapy 2018;99:543-51. [DOI: 10.1016/j.biopha.2018.01.045] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
76 Hehlgans S, Storch K, Lange I, Cordes N. The novel HDAC inhibitor NDACI054 sensitizes human cancer cells to radiotherapy. Radiother Oncol. 2013;109:126-132. [PMID: 24060178 DOI: 10.1016/j.radonc.2013.08.023] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
77 Shah MY, Martinez-Garcia E, Phillip JM, Chambliss AB, Popovic R, Ezponda T, Small EC, Will C, Phillip MP, Neri P, Bahlis NJ, Wirtz D, Licht JD. MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents. Oncogene 2016;35:5905-15. [PMID: 27109101 DOI: 10.1038/onc.2016.116] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 7.3] [Reference Citation Analysis]
78 Yazbeck VY, Grant S. Romidepsin for the treatment of non-Hodgkin's lymphoma. Expert Opin Investig Drugs 2015;24:965-79. [PMID: 25936363 DOI: 10.1517/13543784.2015.1041586] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
79 Li Z, Zhu WG. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications. Int J Biol Sci. 2014;10:757-770. [PMID: 25013383 DOI: 10.7150/ijbs.9067] [Cited by in Crossref: 88] [Cited by in F6Publishing: 84] [Article Influence: 11.0] [Reference Citation Analysis]
80 Wawruszak A, Luszczki JJ, Grabarska A, Gumbarewicz E, Dmoszynska-Graniczka M, Polberg K, Stepulak A. Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis. PLoS One 2015;10:e0143013. [PMID: 26580554 DOI: 10.1371/journal.pone.0143013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
81 Prado G, Kaestner CL, Licht JD, Bennett RL. Targeting epigenetic mechanisms to overcome venetoclax resistance. Biochim Biophys Acta Mol Cell Res 2021;1868:119047. [PMID: 33945824 DOI: 10.1016/j.bbamcr.2021.119047] [Reference Citation Analysis]
82 Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther. 2014;143:323-336. [PMID: 24769080 DOI: 10.1016/j.pharmthera.2014.04.004] [Cited by in Crossref: 152] [Cited by in F6Publishing: 143] [Article Influence: 19.0] [Reference Citation Analysis]
83 Kim MJ, Lee JS, Park SE, Yi H, Jeong IG, Kang JS, Yun J, Lee J, Ro S, Lee JS, Choi EK, Hwang JJ, Kim C. Combination Treatment of Renal Cell Carcinoma with Belinostat and 5-Fluorouracil: A Role for Oxidative Stress Induced DNA Damage and HSP90 Regulated Thymidine Synthase. Journal of Urology 2015;193:1660-8. [DOI: 10.1016/j.juro.2014.11.091] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
84 Stengel KR, Hiebert SW. Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy. Antioxid Redox Signal 2015;23:51-65. [PMID: 24730655 DOI: 10.1089/ars.2014.5915] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
85 Li L, Sun Y, Liu J, Wu X, Chen L, Ma L, Wu P. Histone deacetylase inhibitor sodium butyrate suppresses DNA double strand break repair induced by etoposide more effectively in MCF-7 cells than in HEK293 cells. BMC Biochem 2015;16:2. [PMID: 25592494 DOI: 10.1186/s12858-014-0030-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
86 Yu L, Lang Y, Guo J, Cai J, Shang ZF, Chen BPC. DNA-PKcs inhibition impairs HDAC6-mediated HSP90 chaperone function on Aurora A and enhances HDACs inhibitor-induced cell killing by increasing mitotic aberrant spindle assembly. Cell Cycle 2021;20:211-24. [PMID: 33404279 DOI: 10.1080/15384101.2020.1867790] [Reference Citation Analysis]
87 Gómez-González B, Ortega P, Aguilera A. Histone deacetylases facilitate the accurate repair of broken forks. Mol Cell Oncol 2020;7:1705731. [PMID: 32158920 DOI: 10.1080/23723556.2019.1705731] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
88 Ahrens TD, Timme S, Hoeppner J, Ostendorp J, Hembach S, Follo M, Hopt UT, Werner M, Busch H, Boerries M. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine. Epigenetics. 2015;10:431-445. [PMID: 25923331 DOI: 10.1080/15592294.2015.1039216] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
89 Heers H, Stanislaw J, Harrelson J, Lee MW. Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer. European Journal of Pharmacology 2018;835:61-74. [DOI: 10.1016/j.ejphar.2018.07.057] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
90 Thurn KT, Thomas S, Raha P, Qureshi I, Munster PN. Histone deacetylase regulation of ATM-mediated DNA damage signaling. Mol Cancer Ther 2013;12:2078-87. [PMID: 23939379 DOI: 10.1158/1535-7163.MCT-12-1242] [Cited by in Crossref: 64] [Cited by in F6Publishing: 49] [Article Influence: 7.1] [Reference Citation Analysis]
91 Pacheco MB, Camilo V, Lopes N, Moreira-Silva F, Correia MP, Henrique R, Jerónimo C. Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines. Pharmaceuticals (Basel) 2021;14:670. [PMID: 34358096 DOI: 10.3390/ph14070670] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
92 Xu QY, Yu L. Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors. Chin Med J (Engl) 2020;:699-715. [PMID: 32044818 DOI: 10.1097/CM9.0000000000000685] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
93 Igaz N, Szőke K, Kovács D, Buhala A, Varga Z, Bélteky P, Rázga Z, Tiszlavicz L, Vizler C, Hideghéty K, Kónya Z, Kiricsi M. Synergistic Radiosensitization by Gold Nanoparticles and the Histone Deacetylase Inhibitor SAHA in 2D and 3D Cancer Cell Cultures. Nanomaterials 2020;10:158. [DOI: 10.3390/nano10010158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
94 McIntyre RL, Daniels EG, Molenaars M, Houtkooper RH, Janssens GE. From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugs. EMBO Mol Med 2019;11:e9854. [PMID: 31368626 DOI: 10.15252/emmm.201809854] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 10.7] [Reference Citation Analysis]
95 Myung JK, Sadar MD. Large scale phosphoproteome analysis of LNCaP human prostate cancer cells. Mol Biosyst 2012;8:2174-82. [PMID: 22699815 DOI: 10.1039/c2mb25151e] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
96 Chen H, Li H, Liu Z, Li J. In Vitro and In Vivo Effects of the Polymyxin-Vorinostat Combination Therapy Against Multidrug-Resistant Gram-Negative Pathogens. Microb Drug Resist 2020;26:1108-19. [PMID: 32349617 DOI: 10.1089/mdr.2019.0309] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
97 Mancini M, Magnani E, Macchi F, Bonapace IM. The multi-functionality of UHRF1: epigenome maintenance and preservation of genome integrity. Nucleic Acids Res 2021;49:6053-68. [PMID: 33939809 DOI: 10.1093/nar/gkab293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
98 Doktorova TY, Ellinger-Ziegelbauer H, Vinken M, Vanhaecke T, van Delft J, Kleinjans J, Ahr HJ, Rogiers V. Comparison of genotoxicant-modified transcriptomic responses in conventional and epigenetically stabilized primary rat hepatocytes with in vivo rat liver data. Arch Toxicol 2012;86:1703-15. [PMID: 23052194 DOI: 10.1007/s00204-012-0946-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
99 Molokie R, Lavelle D, Gowhari M, Pacini M, Krauz L, Hassan J, Ibanez V, Ruiz MA, Ng KP, Woost P, Radivoyevitch T, Pacelli D, Fada S, Rump M, Hsieh M, Tisdale JF, Jacobberger J, Phelps M, Engel JD, Saraf S, Hsu LL, Gordeuk V, DeSimone J, Saunthararajah Y. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study. PLoS Med 2017;14:e1002382. [PMID: 28880867 DOI: 10.1371/journal.pmed.1002382] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 13.6] [Reference Citation Analysis]
100 Berendsen S, Broekman M, Seute T, Snijders T, van Es C, de Vos F, Regli L, Robe P. Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results. Expert Opinion on Investigational Drugs 2012;21:1391-415. [DOI: 10.1517/13543784.2012.694425] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
101 Ververis K, Rodd AL, Tang MM, El-osta A, Karagiannis TC. Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes. Cell Mol Life Sci 2011;68:4101-14. [DOI: 10.1007/s00018-011-0727-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
102 Ueki N, Lee S, Sampson NS, Hayman MJ. Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease. Nat Commun 2013;4. [DOI: 10.1038/ncomms3735] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 6.0] [Reference Citation Analysis]
103 Aru B, Günay A, Şenkuytu E, Yanıkkaya Demirel G, Gürek AG, Atilla D. A Translational Study of a Silicon Phthalocyanine Substituted with a Histone Deacetylase Inhibitor for Photodynamic Therapy. ACS Omega 2020;5:25854-67. [PMID: 33073111 DOI: 10.1021/acsomega.0c03180] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
104 Griffith DM, Bíró L, Platts JA, Müller-bunz H, Farkas E, Buglyó P. Synthesis and solution behaviour of stable mono-, di- and trinuclear Pd(II) complexes of 2,5-pyridinedihydroxamic acid: X-ray crystal structure of a novel Pd(II) hydroxamato complex. Inorganica Chimica Acta 2012;380:291-300. [DOI: 10.1016/j.ica.2011.09.050] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
105 Rosato R, Hock S, Dent P, Dai Y, Grant S. LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism. Leuk Res 2012;36:491-8. [PMID: 22074700 DOI: 10.1016/j.leukres.2011.10.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
106 Gouraud A, Brazeau MA, Grégoire MC, Simard O, Massonneau J, Arguin M, Boissonneault G. "Breaking news" from spermatids. Basic Clin Androl 2013;23:11. [PMID: 25780573 DOI: 10.1186/2051-4190-23-11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
107 Jiang W, Li Q, Zhu Z, Wang Q, Dou J, Zhao Y, Lv W, Zhong F, Yao Y, Zhang G, Liu H, Wang Y, Wang J. Cancer Chemoradiotherapy Duo: Nano-Enabled Targeting of DNA Lesion Formation and DNA Damage Response. ACS Appl Mater Interfaces 2018;10:35734-44. [DOI: 10.1021/acsami.8b10901] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
108 Manal M, Chandrasekar M, Gomathi Priya J, Nanjan M. Inhibitors of histone deacetylase as antitumor agents: A critical review. Bioorganic Chemistry 2016;67:18-42. [DOI: 10.1016/j.bioorg.2016.05.005] [Cited by in Crossref: 124] [Cited by in F6Publishing: 103] [Article Influence: 20.7] [Reference Citation Analysis]
109 Ungerstedt JS. Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors. Int J Mol Sci 2018;19:E3091. [PMID: 30304859 DOI: 10.3390/ijms19103091] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
110 Chen X, Radany EH, Wong P, Ma S, Wu K, Wang B, Wong JY. Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants. PLoS One 2013;8:e84515. [PMID: 24367670 DOI: 10.1371/journal.pone.0084515] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
111 Wang EC, Min Y, Palm RC, Fiordalisi JJ, Wagner KT, Hyder N, Cox AD, Caster JM, Tian X, Wang AZ. Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors. Biomaterials 2015;51:208-15. [PMID: 25771011 DOI: 10.1016/j.biomaterials.2015.02.015] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
112 Colis LC, Herzon SB. Synergistic potentiation of (-)-lomaiviticin A cytotoxicity by the ATR inhibitor VE-821. Bioorg Med Chem Lett 2016;26:3122-6. [PMID: 27177826 DOI: 10.1016/j.bmcl.2016.04.090] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
113 Yang L, Qu M, Wang Y, Duan H, Chen P, Wang Y, Shi W, Danielson P, Zhou Q. Trichostatin A inhibits transforming growth factor-β-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling. Mol Pharmacol 2013;83:671-80. [PMID: 23284002 DOI: 10.1124/mol.112.081059] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
114 Jia X, Zheng Y, Guo Y, Chen K. Sodium butyrate and panobinostat induce apoptosis of chronic myeloid leukemia cells via multiple pathways. Mol Genet Genomic Med 2019;7:e613. [PMID: 30891950 DOI: 10.1002/mgg3.613] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
115 Lee JH, Marks PA. Histone deacetylase inhibitors in the therapy of cancer: much to learn. Epigenomics. 2010;2:723-725. [PMID: 22122077 DOI: 10.2217/epi.10.59] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
116 Dong M, Liu F, Zhou H, Zhai S, Yan B. Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding Site. Molecules 2016;21:E1375. [PMID: 27754459 DOI: 10.3390/molecules21101375] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
117 Neri P, Bahlis NJ, Lonial S. Panobinostat for the treatment of multiple myeloma. Expert Opinion on Investigational Drugs 2012;21:733-47. [DOI: 10.1517/13543784.2012.668883] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
118 Wilson AJ, Cheng YQ, Khabele D. Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy. J Ovarian Res 2012;5:12. [PMID: 22531354 DOI: 10.1186/1757-2215-5-12] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
119 Lu H, Bai L, Zhou Y, Lu Y, Jiang Z, Shi J. Recent Study of Dual HDAC/PARP Inhibitor for the Treatment of Tumor. CTMC 2019;19:1041-50. [DOI: 10.2174/1568026619666190603092407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
120 Dincman TA, Beare JE, Ohri SS, Gallo V, Hetman M, Whittemore SR. Histone deacetylase inhibition is cytotoxic to oligodendrocyte precursor cells in vitro and in vivo. Int J Dev Neurosci 2016;54:53-61. [PMID: 27587342 DOI: 10.1016/j.ijdevneu.2016.08.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
121 Groselj B, Ruan JL, Scott H, Gorrill J, Nicholson J, Kelly J, Anbalagan S, Thompson J, Stratford MRL, Jevons SJ, Hammond EM, Scudamore CL, Kerr M, Kiltie AE. Radiosensitization In Vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity. Mol Cancer Ther 2018;17:381-92. [PMID: 28839000 DOI: 10.1158/1535-7163.MCT-17-0011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
122 Wang X, Liu K, Gong H, Li D, Chu W, Zhao D, Wang X, Xu D. Death by histone deacetylase inhibitor quisinostat in tongue squamous cell carcinoma via apoptosis, pyroptosis, and ferroptosis. Toxicol Appl Pharmacol 2021;410:115363. [PMID: 33290780 DOI: 10.1016/j.taap.2020.115363] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
123 Lee JH, Yao Y, Mahendran A, Ngo L, Venta-Perez G, Choy ML, Breslow R, Marks PA. Creation of a histone deacetylase 6 inhibitor and its biological effects [corrected]. Proc Natl Acad Sci U S A 2015;112:12005-10. [PMID: 26371309 DOI: 10.1073/pnas.1515882112] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
124 Saha B, Parks RJ. Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Suppresses Human Adenovirus Gene Expression and Replication. J Virol 2019;93:e00088-19. [PMID: 30944181 DOI: 10.1128/JVI.00088-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
125 Jespersen H, Olofsson Bagge R, Ullenhag G, Carneiro A, Helgadottir H, Ljuslinder I, Levin M, All-Eriksson C, Andersson B, Stierner U, Nilsson LM, Nilsson JA, Ny L. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. BMC Cancer 2019;19:415. [PMID: 31046743 DOI: 10.1186/s12885-019-5623-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
126 Nguyen T, Parker R, Hawkins E, Holkova B, Yazbeck V, Kolluri A, Kmieciak M, Rahmani M, Grant S. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms. Oncotarget 2017;8:31478-93. [PMID: 28416758 DOI: 10.18632/oncotarget.15649] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
127 Lai LC, Tsai MH, Chen PC, Chen LH, Hsiao JH, Chen SK, Lu TP, Lee JM, Hsu CP, Hsiao CK, Chuang EY. SNP rs10248565 in HDAC9 as a novel genomic aberration biomarker of lung adenocarcinoma in non-smoking women. J Biomed Sci 2014;21:24. [PMID: 24650256 DOI: 10.1186/1423-0127-21-24] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
128 Wilson AJ, Holson E, Wagner F, Zhang YL, Fass DM, Haggarty SJ, Bhaskara S, Hiebert SW, Schreiber SL, Khabele D. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. Cancer Biol Ther 2011;12:484-93. [PMID: 21738006 DOI: 10.4161/cbt.12.6.15956] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
129 Groselj B, Sharma NL, Hamdy FC, Kerr M, Kiltie AE. Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer 2013;108:748-54. [PMID: 23361058 DOI: 10.1038/bjc.2013.21] [Cited by in Crossref: 114] [Cited by in F6Publishing: 109] [Article Influence: 12.7] [Reference Citation Analysis]
130 Veronezi GM, Felisbino MB, Gatti MS, Mello ML, Vidal BC. DNA Methylation Changes in Valproic Acid-Treated HeLa Cells as Assessed by Image Analysis, Immunofluorescence and Vibrational Microspectroscopy. PLoS One 2017;12:e0170740. [PMID: 28114349 DOI: 10.1371/journal.pone.0170740] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
131 Thotala D, Karvas RM, Engelbach JA, Garbow JR, Hallahan AN, DeWees TA, Laszlo A, Hallahan DE. Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells. Oncotarget 2015;6:35004-22. [PMID: 26413814 DOI: 10.18632/oncotarget.5253] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
132 Masadeh MM, Alzoubi KH, Al-Azzam SI, Al-Buhairan AM. Possible involvement of ROS generation in vorinostat pretreatment induced enhancement of the antibacterial activity of ciprofloxacin. Clin Pharmacol 2017;9:119-24. [PMID: 29081676 DOI: 10.2147/CPAA.S148448] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
133 Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Flatmark K, Lyng H. Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition. Br J Cancer 2016;115:929-39. [PMID: 27599042 DOI: 10.1038/bjc.2016.278] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
134 Wang Y, Stowe RL, Pinello CE, Tian G, Madoux F, Li D, Zhao LY, Li JL, Wang Y, Wang Y, Ma H, Hodder P, Roush WR, Liao D. Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases. Chem Biol 2015;22:273-84. [PMID: 25699604 DOI: 10.1016/j.chembiol.2014.12.015] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
135 Pinto L, Baidarjad H, Entz-Werlé N, Van Dyck E. Impact of Chromatin Dynamics and DNA Repair on Genomic Stability and Treatment Resistance in Pediatric High-Grade Gliomas. Cancers (Basel) 2021;13:5678. [PMID: 34830833 DOI: 10.3390/cancers13225678] [Reference Citation Analysis]
136 Blanquart C, Linot C, Cartron PF, Tomaselli D, Mai A, Bertrand P. Epigenetic Metalloenzymes. Curr Med Chem 2019;26:2748-85. [PMID: 29984644 DOI: 10.2174/0929867325666180706105903] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
137 Zhu L, Wu K, Ma S, Zhang S. HDAC Inhibitors: A New Radiosensitizer for Non-small-cell Lung Cancer. Tumori 2015;101:257-62. [DOI: 10.5301/tj.5000347] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
138 Buisman SC, de Haan G. Epigenetic Changes as a Target in Aging Haematopoietic Stem Cells and Age-Related Malignancies. Cells 2019;8:E868. [PMID: 31405121 DOI: 10.3390/cells8080868] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
139 Lee JH, Mahendran A, Yao Y, Ngo L, Venta-Perez G, Choy ML, Kim N, Ham WS, Breslow R, Marks PA. Development of a histone deacetylase 6 inhibitor and its biological effects. Proc Natl Acad Sci U S A 2013;110:15704-9. [PMID: 24023063 DOI: 10.1073/pnas.1313893110] [Cited by in Crossref: 95] [Cited by in F6Publishing: 87] [Article Influence: 10.6] [Reference Citation Analysis]
140 Cappellacci L, Perinelli DR, Maggi F, Grifantini M, Petrelli R. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents. Curr Med Chem 2020;27:2449-93. [PMID: 30332940 DOI: 10.2174/0929867325666181016163110] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 13.0] [Reference Citation Analysis]
141 Mrakovcic M, Kleinheinz J, Fröhlich LF. p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death. Int J Mol Sci 2019;20:E2415. [PMID: 31096697 DOI: 10.3390/ijms20102415] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
142 Cornago M, Garcia-Alberich C, Blasco-Angulo N, Vall-Llaura N, Nager M, Herreros J, Comella JX, Sanchis D, Llovera M. Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe. Cell Death Dis 2014;5:e1435. [PMID: 25275596 DOI: 10.1038/cddis.2014.412] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 7.4] [Reference Citation Analysis]
143 Tomaselli D, Lucidi A, Rotili D, Mai A. Epigenetic polypharmacology: A new frontier for epi-drug discovery. Med Res Rev 2020;40:190-244. [PMID: 31218726 DOI: 10.1002/med.21600] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 12.3] [Reference Citation Analysis]
144 Ye J, Li J, Zhou M, Xia R, Liu R, Yu L. Modulation of Donor-Specific Antibody Production After Organ Transplantation by Valproic Acid: A Histone Deacetylase Inhibitor. Transplantation 2016;100:2342-51. [PMID: 27140514 DOI: 10.1097/TP.0000000000001197] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
145 Wang L, Syn NL, Subhash VV, Any Y, Thuya WL, Cheow ESH, Kong L, Yu F, Peethala PC, Wong AL, Laljibhai HJ, Chinnathambi A, Ong PS, Ho PC, Sethi G, Yong WP, Goh BC. Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling. Cancer Letters 2018;417:152-60. [DOI: 10.1016/j.canlet.2017.12.030] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 9.5] [Reference Citation Analysis]
146 Seah KS, Loh JY, Nguyen TTT, Tan HL, Hutchinson PE, Lim KK, Dymock BW, Long YC, Lee EJD, Shen HM, Chen ES. SAHA and cisplatin sensitize gastric cancer cells to doxorubicin by induction of DNA damage, apoptosis and perturbation of AMPK-mTOR signalling. Exp Cell Res. 2018;370:283-291. [PMID: 29959912 DOI: 10.1016/j.yexcr.2018.06.029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
147 Groselj B, Kerr M, Kiltie AE. Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression. Radiother Oncol 2013;108:429-33. [PMID: 23932191 DOI: 10.1016/j.radonc.2013.06.021] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
148 Rajendran P, Ho E, Williams DE, Dashwood RH. Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells. Clin Epigenetics 2011;3:4. [PMID: 22247744 DOI: 10.1186/1868-7083-3-4] [Cited by in Crossref: 132] [Cited by in F6Publishing: 122] [Article Influence: 12.0] [Reference Citation Analysis]
149 Lernoux M, Schnekenburger M, Losson H, Vermeulen K, Hahn H, Gérard D, Lee JY, Mazumder A, Ahamed M, Christov C, Kim DW, Dicato M, Bormans G, Han BW, Diederich M. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells. Clin Epigenetics 2020;12:69. [PMID: 32430012 DOI: 10.1186/s13148-020-00839-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
150 Yaseen A, Chen S, Hock S, Rosato R, Dent P, Dai Y, Grant S. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway. Mol Pharmacol 2012;82:1030-41. [PMID: 22923501 DOI: 10.1124/mol.112.079624] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
151 Liu T, Wan Y, Xiao Y, Xia C, Duan G. Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy. J Med Chem 2020;63:8977-9002. [PMID: 32320239 DOI: 10.1021/acs.jmedchem.0c00491] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
152 Gołąbek K, Strzelczyk JK, Wiczkowski A, Michalski M. Potential use of histone deacetylase inhibitors in cancer therapy. Contemp Oncol (Pozn) 2015;19:436-40. [PMID: 26843838 DOI: 10.5114/wo.2015.51824] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
153 Attia SM, Al-Hamamah MA, Alotaibi MR, Harisa GI, Attia MM, Ahmad SF, Ansari MA, Nadeem A, Bakheet SA. Investigation of belinostat-induced genomic instability by molecular cytogenetic analysis and pathway-focused gene expression profiling. Toxicol Appl Pharmacol 2018;350:43-51. [PMID: 29733868 DOI: 10.1016/j.taap.2018.05.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
154 Rahmani M, Aust MM, Benson EC, Wallace L, Friedberg J, Grant S. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo. Clin Cancer Res 2014;20:4849-60. [PMID: 25070836 DOI: 10.1158/1078-0432.CCR-14-0034] [Cited by in Crossref: 56] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
155 Guo H, Zeng D, Zhang H, Bell T, Yao J, Liu Y, Huang S, Li CJ, Lorence E, Zhou S, Gong T, Jiang C, Ahmed M, Yao Y, Nomie KJ, Zhang L, Wang M. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Oncogene 2019;38:1802-14. [PMID: 30361685 DOI: 10.1038/s41388-018-0550-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
156 Dewaker V, Srivastava AK, Arora A, Prabhakar YS. Investigation of HDAC8-ligands’ intermolecular forces through molecular dynamics simulations: profiling of non-bonding energies to design potential compounds as new anti-cancer agents. Journal of Biomolecular Structure and Dynamics 2021;39:4726-51. [DOI: 10.1080/07391102.2020.1780940] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
157 Nguyen TT, Chua JK, Seah KS, Koo SH, Yee JY, Yang EG, Lim KK, Pang SY, Yuen A, Zhang L, Ang WH, Dymock B, Lee EJ, Chen ES. Predicting chemotherapeutic drug combinations through gene network profiling. Sci Rep 2016;6:18658. [PMID: 26791325 DOI: 10.1038/srep18658] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
158 Gammoh N, Lam D, Puente C, Ganley I, Marks PA, Jiang X. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc Natl Acad Sci U S A 2012;109:6561-5. [PMID: 22493260 DOI: 10.1073/pnas.1204429109] [Cited by in Crossref: 146] [Cited by in F6Publishing: 135] [Article Influence: 14.6] [Reference Citation Analysis]
159 Perego P, Zuco V, Gatti L, Zunino F. Sensitization of tumor cells by targeting histone deacetylases. Biochem Pharmacol 2012;83:987-94. [PMID: 22120677 DOI: 10.1016/j.bcp.2011.11.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
160 Tse KH, Herrup K. DNA damage in the oligodendrocyte lineage and its role in brain aging. Mech Ageing Dev 2017;161:37-50. [PMID: 27235538 DOI: 10.1016/j.mad.2016.05.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 6.8] [Reference Citation Analysis]
161 Ladd B, Ackroyd JJ, Hicks JK, Canman CE, Flanagan SA, Shewach DS. Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity. DNA Repair (Amst) 2013;12:1114-21. [PMID: 24231389 DOI: 10.1016/j.dnarep.2013.10.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
162 Spiegel S, Milstien S, Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 2012;31:537-51. [PMID: 21725353 DOI: 10.1038/onc.2011.267] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 8.8] [Reference Citation Analysis]
163 Tsuboi K. Advantages and Limitations in the Use of Combination Therapies with Charged Particle Radiation Therapy. Int J Part Ther 2018;5:122-32. [PMID: 31773024 DOI: 10.14338/IJPT-18-00019.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
164 Mrakovcic M, Kleinheinz J, Fröhlich LF. Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53. Int J Mol Sci 2017;18:E1883. [PMID: 30563957 DOI: 10.3390/ijms18091883] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
165 Zhang B, Lyu J, Yang EJ, Liu Y, Wu C, Pardeshi L, Tan K, Chen Q, Xu X, Deng CX, Shim JS. Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells. Acta Pharm Sin B 2020;10:615-27. [PMID: 32322466 DOI: 10.1016/j.apsb.2019.08.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
166 Song G, Valdez BC, Li Y, Dominguez JR, Corn P, Champlin RE, Andersson BS. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. Leuk Lymphoma 2014;55:1625-34. [PMID: 24144307 DOI: 10.3109/10428194.2013.856007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
167 Pinazza M, Borga C, Agnusdei V, Minuzzo S, Fossati G, Paganin M, Michielotto B, De Paoli A, Basso G, Amadori A, te Kronnie G, Indraccolo S. An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts. Cell Death Dis 2016;6:e2047. [PMID: 26764573 DOI: 10.1038/cddis.2015.394] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
168 Schizas D, Mastoraki A, Naar L, Spartalis E, Tsilimigras DI, Karachaliou GS, Bagias G, Moris D. Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment. World J Gastroenterol 2018; 24(41): 4635-4642 [PMID: 30416311 DOI: 10.3748/wjg.v24.i41.4635] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
169 Dallavalle S, Pisano C, Zunino F. Development and therapeutic impact of HDAC6-selective inhibitors. Biochemical Pharmacology 2012;84:756-65. [DOI: 10.1016/j.bcp.2012.06.014] [Cited by in Crossref: 97] [Cited by in F6Publishing: 95] [Article Influence: 9.7] [Reference Citation Analysis]
170 Guo SQ, Zhang YZ. Histone deacetylase inhibition: an important mechanism in the treatment of lymphoma. Cancer Biol Med 2012;9:85-9. [PMID: 23691460 DOI: 10.3969/j.issn.2095-3941.2012.02.001] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
171 Lee JH, Choy ML, Ngo L, Venta-Perez G, Marks PA. Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2011;108:19629-34. [PMID: 22106282 DOI: 10.1073/pnas.1117544108] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
172 Li H, Ma L, Bian X, Lv Y, Lin W. FK228 sensitizes radioresistant small cell lung cancer cells to radiation. Clin Epigenetics 2021;13:41. [PMID: 33632300 DOI: 10.1186/s13148-021-01025-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Gerelchuluun A, Maeda J, Manabe E, Brents CA, Sakae T, Fujimori A, Chen DJ, Tsuboi K, Kato TA. Histone Deacetylase Inhibitor Induced Radiation Sensitization Effects on Human Cancer Cells after Photon and Hadron Radiation Exposure. Int J Mol Sci 2018;19:E496. [PMID: 29414878 DOI: 10.3390/ijms19020496] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
174 Dai Y, Chen S, Wang L, Pei XY, Kramer LB, Dent P, Grant S. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim. Br J Haematol 2011;153:222-35. [PMID: 21375523 DOI: 10.1111/j.1365-2141.2011.08591.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
175 Yalon M, Tuval-Kochen L, Castel D, Moshe I, Mazal I, Cohen O, Avivi C, Rosenblatt K, Aviel-Ronen S, Schiby G, Yahalom J, Amariglio N, Pfeffer R, Lawrence Y, Toren A, Rechavi G, Paglin S. Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations. PLoS One 2016;11:e0155711. [PMID: 27196668 DOI: 10.1371/journal.pone.0155711] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
176 Hagiwara K, Kunishima S, Iida H, Miyata Y, Naoe T, Nagai H. The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line. Apoptosis 2015;20:975-85. [DOI: 10.1007/s10495-015-1125-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
177 Rangwala S, Zhang C, Duvic M. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. Future Med Chem 2012;4:471-86. [PMID: 22416775 DOI: 10.4155/fmc.12.6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 4.6] [Reference Citation Analysis]
178 Lopez G, Torres K, Liu J, Hernandez B, Young E, Belousov R, Bolshakov S, Lazar AJ, Slopis JM, McCutcheon IE. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res. 2011;71:185-196. [PMID: 21084276 DOI: 10.1158/0008-5472.can-10-2799] [Cited by in Crossref: 63] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
179 Zhao J, Zhou M, Li C. Synthetic nanoparticles for delivery of radioisotopes and radiosensitizers in cancer therapy. Cancer Nanotechnol 2016;7:9. [PMID: 27909463 DOI: 10.1186/s12645-016-0022-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
180 Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 2011;7:263-83. [PMID: 21345145 DOI: 10.2217/fon.11.2] [Cited by in Crossref: 166] [Cited by in F6Publishing: 157] [Article Influence: 15.1] [Reference Citation Analysis]
181 Peng Q, Weng K, Li S, Xu R, Wang Y, Wu Y. A Perspective of Epigenetic Regulation in Radiotherapy. Front Cell Dev Biol 2021;9:624312. [PMID: 33681204 DOI: 10.3389/fcell.2021.624312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
182 Sharda A, Rashid M, Shah SG, Sharma AK, Singh SR, Gera P, Chilkapati MK, Gupta S. Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells. Clin Epigenetics 2020;12:4. [PMID: 31900196 DOI: 10.1186/s13148-019-0800-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
183 Shi ZJ, Ouyang DY, Zhu JS, Xu LH, He XH. Histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits anti-inflammatory activities through induction of mitochondrial damage and apoptosis in activated lymphocytes. Int Immunopharmacol 2012;12:580-7. [PMID: 22369900 DOI: 10.1016/j.intimp.2012.02.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
184 Suraweera A, O'Byrne KJ, Richard DJ. Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. Front Oncol 2018;8:92. [PMID: 29651407 DOI: 10.3389/fonc.2018.00092] [Cited by in Crossref: 288] [Cited by in F6Publishing: 251] [Article Influence: 72.0] [Reference Citation Analysis]
185 Qiu W, Ding X, Li S, He Y, Zhu L. Oncolytic Bovine Herpesvirus 1 Inhibits Human Lung Adenocarcinoma A549 Cell Proliferation and Tumor Growth by Inducing DNA Damage. Int J Mol Sci 2021;22:8582. [PMID: 34445287 DOI: 10.3390/ijms22168582] [Reference Citation Analysis]
186 Xie R, Li Y, Tang P, Yuan Q. Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity. Bioorganic & Medicinal Chemistry Letters 2017;27:4415-20. [DOI: 10.1016/j.bmcl.2017.08.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
187 Attia SM, Al-Khalifa MK, Al-Hamamah MA, Alotaibi MR, Attia MSM, Ahmad SF, Ansari MA, Nadeem A, Bakheet SA. Vorinostat is genotoxic and epigenotoxic in the mouse bone marrow cells at the human equivalent doses. Toxicology 2020;441:152507. [PMID: 32512035 DOI: 10.1016/j.tox.2020.152507] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
188 Stubbs MC, Kim W, Bariteau M, Davis T, Vempati S, Minehart J, Witkin M, Qi J, Krivtsov AV, Bradner JE, Kung AL, Armstrong SA. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clin Cancer Res 2015;21:2348-58. [PMID: 25688158 DOI: 10.1158/1078-0432.CCR-14-1290] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
189 de Zoeten EF, Wang L, Butler K, Beier UH, Akimova T, Sai H, Bradner JE, Mazitschek R, Kozikowski AP, Matthias P, Hancock WW. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol 2011;31:2066-78. [PMID: 21444725 DOI: 10.1128/MCB.05155-11] [Cited by in Crossref: 170] [Cited by in F6Publishing: 104] [Article Influence: 15.5] [Reference Citation Analysis]
190 Anantharaju PG, Reddy DB, Padukudru MA, Chitturi CMK, Vimalambike MG, Madhunapantula SV. Induction of colon and cervical cancer cell death by cinnamic acid derivatives is mediated through the inhibition of Histone Deacetylases (HDAC). PLoS One 2017;12:e0186208. [PMID: 29190639 DOI: 10.1371/journal.pone.0186208] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
191 Maugeri-Sacc拉 M, Bartucci M, De Maria R. Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy. Cancer Treat Rev. 2013;39:525-533. [PMID: 23207059 DOI: 10.1016/j.ctrv.2012.10.007] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
192 Cassandri M, Pomella S, Rossetti A, Petragnano F, Milazzo L, Vulcano F, Camero S, Codenotti S, Cicchetti F, Maggio R, Festuccia C, Gravina GL, Fanzani A, Megiorni F, Catanoso M, Marchese C, Tombolini V, Locatelli F, Rota R, Marampon F. MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells. Int J Mol Sci 2021;22:10671. [PMID: 34639012 DOI: 10.3390/ijms221910671] [Reference Citation Analysis]
193 Gkotzamanidou M, Terpou E, Kentepozidis N, Terpos E. Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy. Int J Mol Sci 2021;22:10406. [PMID: 34638744 DOI: 10.3390/ijms221910406] [Reference Citation Analysis]
194 Seifrtová M, Havelek R, Cahlíková L, Hulcová D, Mazánková N, Řezáčová M. Haemanthamine alters sodium butyrate-induced histone acetylation, p21 WAF1/Cip1 expression, Chk1 and Chk2 activation and leads to increased growth inhibition and death in A2780 ovarian cancer cells. Phytomedicine 2017;35:1-10. [DOI: 10.1016/j.phymed.2017.08.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
195 Mrakovcic M, Bohner L, Hanisch M, Fröhlich LF. Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53. Int J Mol Sci 2018;19:E3952. [PMID: 30544838 DOI: 10.3390/ijms19123952] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
196 Yang B, Yu D, Liu J, Yang K, Wu G, Liu H. Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo. Tumour Biol. 2015;36:5051-5061. [PMID: 25649979 DOI: 10.1007/s13277-015-3156-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
197 Diyabalanage HV, Granda ML, Hooker JM. Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett 2013;329:1-8. [PMID: 23032720 DOI: 10.1016/j.canlet.2012.09.018] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 5.8] [Reference Citation Analysis]
198 Song YW, Lim Y, Cho SK. 2,4‑Di‑tert‑butylphenol, a potential HDAC6 inhibitor, induces senescence and mitotic catastrophe in human gastric adenocarcinoma AGS cells. Biochim Biophys Acta Mol Cell Res 2018;1865:675-83. [PMID: 29427610 DOI: 10.1016/j.bbamcr.2018.02.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
199 Ali A, Bluteau O, Messaoudi K, Palazzo A, Boukour S, Lordier L, Lecluse Y, Rameau P, Kraus-Berthier L, Jacquet-Bescond A, Lelièvre H, Depil S, Dessen P, Solary E, Raslova H, Vainchenker W, Plo I, Debili N. Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms. Cell Death Dis 2013;4:e738. [PMID: 23887629 DOI: 10.1038/cddis.2013.260] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
200 Di Costanzo A, Del Gaudio N, Migliaccio A, Altucci L. Epigenetic drugs against cancer: an evolving landscape. Arch Toxicol 2014;88:1651-68. [DOI: 10.1007/s00204-014-1315-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
201 Kavianpour P, Gemmell MCM, Kahlert JU, Rendina LM. Histone Deacetylase 2 (HDAC2) Inhibitors Containing Boron. ChemBioChem 2020;21:2786-91. [DOI: 10.1002/cbic.202000131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
202 Wilson AJ, Lalani AS, Wass E, Saskowski J, Khabele D. Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer. Gynecol Oncol. 2012;127:579-586. [PMID: 23010348 DOI: 10.1016/j.ygyno.2012.09.016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
203 Garmpis N, Damaskos C, Garmpi A, Kalampokas E, Kalampokas T, Spartalis E, Daskalopoulou A, Valsami S, Kontos M, Nonni A, Kontzoglou K, Perrea D, Nikiteas N, Dimitroulis D. Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises. Cancer Genomics Proteomics 2017;14:299-313. [PMID: 28870998 DOI: 10.21873/cgp.20041] [Cited by in Crossref: 8] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
204 Kearney M, Cooper PR, Smith AJ, Duncan HF. Epigenetic Approaches to the Treatment of Dental Pulp Inflammation and Repair: Opportunities and Obstacles. Front Genet 2018;9:311. [PMID: 30131827 DOI: 10.3389/fgene.2018.00311] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
205 Hui KF, Yeung PL, Chiang AK. Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib. Oncotarget 2016;7:4454-67. [PMID: 26683357 DOI: 10.18632/oncotarget.6601] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
206 Giannopoulou AF, Velentzas AD, Konstantakou EG, Avgeris M, Katarachia SA, Papandreou NC, Kalavros NI, Mpakou VE, Iconomidou V, Anastasiadou E, Kostakis IK, Papassideri IS, Voutsinas GE, Scorilas A, Stravopodis DJ. Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer. Int J Mol Sci 2019;20:E1291. [PMID: 30875794 DOI: 10.3390/ijms20061291] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
207 Librizzi M, Caradonna F, Cruciata I, Dębski J, Sansook S, Dadlez M, Spencer J, Luparello C. Molecular Signatures Associated with Treatment of Triple-Negative MDA-MB231 Breast Cancer Cells with Histone Deacetylase Inhibitors JAHA and SAHA. Chem Res Toxicol 2017;30:2187-96. [PMID: 29129070 DOI: 10.1021/acs.chemrestox.7b00269] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
208 Bohrer RC, Duggavathi R, Bordignon V. Inhibition of histone deacetylases enhances DNA damage repair in SCNT embryos. Cell Cycle 2014;13:2138-48. [PMID: 24841373 DOI: 10.4161/cc.29215] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
209 Velcheti V, Schrump D, Saunthararajah Y. Ultimate Precision: Targeting Cancer but Not Normal Self-replication. Am Soc Clin Oncol Educ Book 2018;38:950-63. [PMID: 30231326 DOI: 10.1200/EDBK_199753] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
210 Tombuloglu A, Copoglu H, Aydin-Son Y, Guray NT. In vitro effects of boric acid on human liver hepatoma cell line (HepG2) at the half-maximal inhibitory concentration. J Trace Elem Med Biol 2020;62:126573. [PMID: 32534377 DOI: 10.1016/j.jtemb.2020.126573] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
211 Liang BY, Xiong M, Ji GB, Zhang EL, Zhang ZY, Dong KS, Chen XP, Huang ZY. Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells. J Huazhong Univ Sci Technolog Med Sci 2015;35:535-40. [PMID: 26223923 DOI: 10.1007/s11596-015-1466-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
212 Grant S, Dai Y. Histone deacetylase inhibitors and rational combination therapies. Adv Cancer Res 2012;116:199-237. [PMID: 23088872 DOI: 10.1016/B978-0-12-394387-3.00006-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
213 Wang Y, Hu PC, Ma YB, Fan R, Gao FF, Zhang JW, Wei L. Sodium butyrate-induced apoptosis and ultrastructural changes in MCF-7 breast cancer cells. Ultrastruct Pathol 2016;40:200-4. [PMID: 27158913 DOI: 10.3109/01913123.2016.1170083] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
214 Dewaker V, Srivastava PN, Verma S, Prabhakar YS. Molecular dynamics study of HDAC8-largazole analogues co-crystals for designing potential anticancer compounds. Journal of Biomolecular Structure and Dynamics 2020;38:1197-213. [DOI: 10.1080/07391102.2019.1598497] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
215 Alzoubi KH, Khabour OF, Jaber AG, Al-Azzam SI, Mhaidat NM, Masadeh MM. Tempol prevents genotoxicity induced by vorinostat: role of oxidative DNA damage. Cytotechnology 2014;66:449-55. [PMID: 23761013 DOI: 10.1007/s10616-013-9597-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
216 Carvalho JF, Kanaar R. Targeting homologous recombination-mediated DNA repair in cancer. Expert Opin Ther Targets 2014;18:427-58. [PMID: 24491188 DOI: 10.1517/14728222.2014.882900] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
217 Saunthararajah Y. Targeting sickle cell disease root-cause pathophysiology with small molecules. Haematologica 2019;104:1720-30. [PMID: 31399526 DOI: 10.3324/haematol.2018.207530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
218 Abramova MV, Svetlikova SB, Kukushkin AN, Aksenov ND, Pospelova TV, Pospelov VA. HDAC inhibitor sodium butyrate sensitizes E1A+Ras-transformed cells to DNA damaging agents by facilitating formation and persistence of γH2AX foci. Cancer Biology & Therapy 2014;12:1069-77. [DOI: 10.4161/cbt.12.12.18365] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
219 Brodská B, Holoubek A. Generation of reactive oxygen species during apoptosis induced by DNA-damaging agents and/or histone deacetylase inhibitors. Oxid Med Cell Longev 2011;2011:253529. [PMID: 21949898 DOI: 10.1155/2011/253529] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 3.7] [Reference Citation Analysis]
220 He B, Dai L, Zhang X, Chen D, Wu J, Feng X, Zhang Y, Xie H, Zhou L, Wu J, Zheng S. The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction. Int J Biol Sci 2018;14:1845-58. [PMID: 30443188 DOI: 10.7150/ijbs.27661] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
221 Lee J, Choy ML, Marks PA. Mechanisms of Resistance to Histone Deacetylase Inhibitors. Histone Deacetylase Inhibitors as Cancer Therapeutics. Elsevier; 2012. pp. 39-86. [DOI: 10.1016/b978-0-12-394387-3.00002-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
222 Brabec V, Griffith DM, Kisova A, Kostrhunova H, Zerzankova L, Marmion CJ, Kasparkova J. Valuable insight into the anticancer activity of the platinum-histone deacetylase inhibitor conjugate, cis-[Pt(NH3)2malSAHA-2H)]. Mol Pharm 2012;9:1990-9. [PMID: 22591133 DOI: 10.1021/mp300038f] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
223 Li X, Zhao Y, Jiang W, Li S, Zhan M, Liu H, Zhang C, Liang H, Liu H, Lu L, Wang Y. Ultralong circulating choline phosphate liposomal nanomedicines for cascaded chemo-radiotherapy. Biomater Sci 2019;7:1335-44. [PMID: 30816393 DOI: 10.1039/c9bm00051h] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
224 Bose P, Verstovsek S. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opin Investig Drugs 2016;25:1393-403. [PMID: 27756180 DOI: 10.1080/13543784.2016.1250882] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
225 Chen Q, Ouyang DY, Geng M, Xu LH, Zhang YT, Wang FP, He XH. Valproic acid exhibits biphasic effects on apoptotic cell death of activated lymphocytes through differential modulation of multiple signaling pathways. J Immunotoxicol 2011;8:210-8. [PMID: 21457087 DOI: 10.3109/1547691X.2011.568979] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
226 Regel I, Merkl L, Friedrich T, Burgermeister E, Zimmermann W, Einwächter H, Herrmann K, Langer R, Röcken C, Hofheinz R, Schmid R, Ebert MP. Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2. Gastroenterology 2012;143:99-109.e10. [PMID: 22465428 DOI: 10.1053/j.gastro.2012.03.035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
227 Robert C, Rassool FV. HDAC inhibitors: roles of DNA damage and repair. Adv Cancer Res. 2012;116:87-129. [PMID: 23088869 DOI: 10.1016/b978-0-12-394387-3.00003-3] [Cited by in Crossref: 78] [Cited by in F6Publishing: 50] [Article Influence: 8.7] [Reference Citation Analysis]